Longitudinal Analysis And Sample Collection To Evaluate PML Risk Host Markers for PML Risk Host Markers for PML Risk (SRA-001)
Longitudinal Meta-Analysis and Further Sample Collection To Evaluate Potential Host Markers for PML Risk
Sponsor: Biogen
A observational or N/A phase clinical study on Multiple Sclerosis, this trial is completed. The trial is conducted by Biogen and has accumulated 13 data snapshots since 2014. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
13 versions recorded-
Sep 2024 — Present [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Dec 2021 — Jul 2024 [monthly]
Completed
-
Mar 2021 — Dec 2021 [monthly]
Completed
Status: Recruiting → Completed
-
Jan 2021 — Mar 2021 [monthly]
Recruiting
▶ Show 8 earlier versions
-
Nov 2020 — Jan 2021 [monthly]
Recruiting
-
Mar 2020 — Nov 2020 [monthly]
Recruiting
Status: Active Not Recruiting → Recruiting
-
May 2019 — Mar 2020 [monthly]
Active Not Recruiting
-
Jun 2018 — May 2019 [monthly]
Active Not Recruiting
-
May 2018 — Jun 2018 [monthly]
Active Not Recruiting
-
Apr 2018 — May 2018 [monthly]
Active Not Recruiting
Phase: NA → None
-
Aug 2017 — Apr 2018 [monthly]
Active Not Recruiting NA
-
Jan 2017 — Aug 2017 [monthly]
Active Not Recruiting NA
First recorded
Oct 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Biogen
- Rocky Mountain MS Research Group, LLC
For direct contact, visit the study record on ClinicalTrials.gov .